Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt. Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:
AstraZeneca, Novavax, Sanofi to distribute COVID-19 shots how they see fit
The White House said Thursday that it removed a requirement that is part of the Defense Production Act that gives the U.S. preferential orders for the COVID-19 vaccines developed by AstraZeneca AZN, 0.27%, Novavax Inc. NVAX, +2.67%, and Sanofi SNY, +0.02%. None of these shots have been authorized in the U.S., but the change allows the companies to decide which orders, including from other countries, they will fulfill first. "We are confident in our supply of our authorized vaccines," Jeff Zients, the White House COVID-19 response coordinator, said during a press briefing. The vaccines authorized in the U.S. are the shots developed by Pfizer Inc. PFE, 0.35%, Moderna Inc. MRNA, 3.80%, and Johnson & Johnson JNJ, -0.07%. The U.S. also plans to donate 25 million additional doses of its current supply over the summer, officials said.
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
- Recombinant spike protein antigen (rS-B.1.351) based on the Beta (B.1.351) virus lineage highly immunogenic in mice and produced neutralizing antibodies - Primates boosted with rS-B.1.351 induced strong neutralizing immune response to original SARS-CoV-2, Alpha (B.1.1.7) and Beta (B.1.351) variant strains - Humans immunized with NVX-CoV2373 demonstrated robust antibody responses to original SARS-CoV-2, as well as Alpha (B.1.1.7) and Beta (B.1.351) variant strains - Data available ahead of publication via preprint server, bioRxiv
?. This work demonstrates that variant vaccines that protect against these newly emerging variants have the potential to be highly effective and may produce broader protection against variants we know of and those that will arise in the future. Clinical trials will provide further evidence on the effectiveness of variant vaccines."
FDA Forces Johnson & Johnson To Throw Out 60 Million Doses Of Covid-19 Vaccine
?Johnson & Johnson must destroy 60 million doses of its Covid-19 vaccine because they may be contaminated, according to a New York Times report, while millions of its unused doses were given extra shelf life by regulators.
The next generation Covid-19 vaccines seeking a slice of the market
?Indeed, newcomer Novavax is forecast to overtake Moderna as the second-largest Covid-19 vaccine maker by revenue next year, with estimated sales of $17.9bn in 2022, according to Airfinity, a London-based analytics company.
* Deutsche Bank Real-Time Indikationen basieren auf Preisen von der Deutschen Bank emittierten Produkten. Diese Produkte versuchen, den jeweiligen Index 1:1 zu tracken.
Die Preisstellung erfolgt börsentäglich zwischen 09:15 und 17:15.